VOLUME 2, ISSUE 3, P239-250, JULY 01, 2021
Paul Pirtea, M.D., Claus Yding Andersen, Ph.D., Dominique de Ziegler, M.D., Jean Marc Ayoubi, M.D., Ph.D.
Human menopausal gonadotropins (hMGs) had been developed long before the advent of assisted reproductive technology (ART) for the induction of ovulation in women suffering from hypogonadotropic hypogonadism. The advent of ART offered a new application for hMGs, for inducing multiple follicular ovarian stimulation (OS) in generally normally ovulating women. The advent of follicle-stimulating hormone (FSH) preparations obtained by genetic recombination techniques in the early 1990s, recombinant FSH, was originally seen as an imminent death knell for hMG preparations obtained from menopausal urine. Yet, 25 years later, hMG preparations—now in a highly purified form—are still part of our treatment options for OS in ART.